Institut Pasteur

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Other

Université Paris Descartes

Centre National De La Recherche Scientifique-cnrs

Universite Paris Cité

Inserm (institut National De La Sante Et De La Recherche Medicale)

Inserm

Armelle Phalipon

Philippe J Sansonetti

Laurence Mulard

Farida Nato

Françoise Baleux

Julien Boutet

Cyrille Grandjean

Catherine Guerreiro

Frédéric Belot

Frederic Belot

Pierre Chassagne

Francois Traincard

Franco Felici

Claude Parsot

Laurence Arbibe

Kim Dong Wook

Riccardo Cortese

Jean Pierre Kraehenbuhl

François Traincard

The present invention relates to a conjugate comprising an oligo- or polysaccharide selected from the group consisting of: (X)-{BCDA}-(Y)(X)-{CDAB}-(Y)(X)-{DABC}-(Y)(X)-{ABCD}n-(Y)wherein A, B, C, D, X and Y, x, y and n are as defined in claim, said oligo- or polysaccharide being bound to a carrier.

Glycoconjugates and their use as potential vaccines against infection by

The present invention relates to compounds derived from sugars which reproduce the epitopes ofserotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing ainfection using one or more oligosaccharides or polysaccharides or conjugates thereof.

[object Object]

A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by

The ospF gene ofencodes a phosphatase, which is a member of a new class of phosphatases. The OspF phosphatase inhibits the activity of several proteins either by direct protein modification or transcription downregulation. These proteins include MAP kinase, IL-8, CCL20, IL-12, AP1, CREB, RPA p32, and BCL2 related proteins. Methods for treating diseases using OspF phosphatase, methods for identifying agents that modulate OspF phosphatase's activity, methods for identifying agents that mimic OspF phosphatase's activity, and immunogenic compositions comprising OspF phosphatase are provided. A strain ofcontaining an inactivated ospF gene is also provided.

Targeting the histone code as a bacterial strategy for selectively modulating gene expression

A purified immunogenic polypeptide comprises an epitope unit recognized by a protective monoclonal antibody having a high affinity and a high specificity for a surface polysaccharide of a pathogenic microorganism of bacterial, viral, or fungal origin. The polypeptide is capable of inducing an immune response in vivo against the pathogenic microorganism. The immune response confers protection in mice against challenge with the virulent microorganisms.

Immunogenic polypeptides that mimic a surface polysaccharide antigen of a pathogenic microorganism, method for obtaining the same, and their use in vaccine compositions

Growing community of inventors

Paris, France

Armelle Phalipon